Online citations, reference lists, and bibliographies.
← Back to Search

Diffuse Malignant Mesothelioma Of The Peritoneum And Pleura, Analysis Of Markers

J. Trupiano, K. Geisinger, M. Willingham, Paul Manders, N. Zbieranski, D. Case, E. Levine
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Diffuse malignant mesothelioma of the peritoneum is a rare diagnosis. Despite many histopathologic similarities between peritoneal and pleural tumors, clinical and prognostic features may be quite different. There is a paucity of data evaluating molecular features of peritoneal mesotheliomas. Therefore, we compared the results of a battery of immunohistochemical markers, some with therapeutic implications, in patients with primary peritoneal or pleural mesotheliomas. We examined 24 peritoneal and nine pleural malignant mesotheliomas with a battery of immunohistochemical markers (cytokeratin AE1/3, calretinin, c-kit/CD117, desmin, epidermal growth factor receptor (EGFR), estrogen receptors (ER), progesterone receptors (PR), MIB-1, and cleaved caspase-3) in an attempt to distinguish any differences in this tumor arising in these two distinct locations. The results indicate that the only marker to show a significant difference in its staining pattern between these two sites was EGFR (P=0.0004). In all, 92% (22/24) of peritoneal tumors demonstrated 3+ or 4+ immunoreactivity with EGFR, opposed to only 33% (3/9) pleural tumors. There was no significant difference in immunoreactivity between the pleural and peritoneal tumors with c-kit, ER, PR, cleaved caspase 3, calretinin, and desmin. There was a trend toward increased cytokeratin (P=0.07) and MIB-1 (P=0.08) expression in the peritoneal group. There was no significant difference in age, sex, or histologic subtype between the two locations. In conclusion, despite similarities between peritoneal and pleural mesothelioma, there are differences between this neoplasm arising in these two sites. The EGFR expression is more pronounced in peritoneal tumors compared to pleural tumors. The increased expression of EGFR in the peritoneal lesions may be of clinical significance with the recent emergence of epidermal growth factor receptor-targeted therapies.
This paper references
Prospective trial for the treatment of malignant peritoneal mesothelioma.
B. Loggie (2001)
10.1016/S0046-8177(99)90011-4
The immunohistochemical diagnosis of epithelial mesothelioma.
N. Ordóñez (1999)
10.1378/CHEST.123.2.551
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
10.1046/J.1365-2168.2000.01571.X
Results of treatment of 33 patients with peritoneal mesothelioma
G. Sebbag (2000)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1046/j.1365-2559.2002.01352.x
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum
R. Attanoos (2002)
Diffuse malignant mesothelioma of the pleural space and its management.
L. Zellos (2002)
10.1007/s004280050339
Epithelial mesothelioma with deciduoid features
Z. Orosz (1999)
10.1053/SONC.2002.30234
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
A. Nowak (2002)
10.1210/EN.2002-220692
Long-term apoptotic cell death process with increased expression and activation of caspase-3 and -6 in adult rat germ cells exposed in utero to flutamide.
A. Omezzine (2003)
10.1053/SONC.2002.30235
Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council.
D. Girling (2002)
10.1097/00000478-199810000-00005
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
N. Ordóñez (1998)
10.1001/ARCHSURG.1990.01410230071012
Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature.
J. Asensio (1990)
[Peritoneal mesothelioma].
R. Osieka (1980)
10.1002/path.1289
Comparison of immunohistochemistry for activated caspase‐3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC‐3 subcutaneous xenografts
W. Duan (2003)
10.1097/01.MP.0000083647.69123.5C
c-Kit Is Not Expressed in Malignant Mesothelioma
A. Horvai (2003)
10.1097/00000478-200006000-00006
Epithelial mesothelioma with deciduoid features: report of four cases.
N. Ordóñez (2000)
10.1378/CHEST.121.2.480
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
E. de Bree (2002)
10.1016/S0046-8177(98)90043-0
Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype.
T. Beer (1998)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1038/bjc.1990.207
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
H. Dazzi (1990)
Multicentric randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the british thoracic society and the british medical research council
DJ Girling (2002)
10.1002/cncr.10209
Diffuse malignant epithelial mesotheliomas of the peritoneum in women
S. Kerrigan (2002)
10.1097/00000478-199510000-00003
Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
J. Goldblum (1995)
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
P. Jänne (2002)
10.1097/00000478-199405000-00002
Deciduoid Peritoneal Mesothelioma: An Unusual Phenotype Affecting Young Females
A. Nascimento (1994)
Malignant peritoneal mesothelioma.
A. Ghosh (1977)
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
C. Arteaga (2003)
10.1007/s10434-999-0582-6
Treatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP)
B. Park (1999)



This paper is referenced by
10.1002/jso.21787
Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
D. Baratti (2011)
10.1158/0008-5472.CAN-08-4523
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
G. Pinton (2009)
10.5348/IJCRI-2014-01-443-CR-16
Omental mesothelioma as a diagnostic and therapeutic challenge: A case report
Cihan Akgul Ozmen (2014)
10.1038/modpathol.3800543
Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
N. Ordóñez (2006)
10.1097/01.pap.0000213041.39070.2f
Diagnostic Immunohistochemistry: What can Go Wrong?
H. Yaziji (2006)
10.1007/978-1-59745-225-0_16
Malignant Peritoneal Mesothelioma
David P. Mangiameli (2007)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma
Aliya N. Husain (2017)
10.1016/J.ICA.2009.05.047
Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines
I. Zanellato (2009)
10.1002/DC.20588
Kallikrein 4 is expressed in malignant mesothelioma—Further evidence for the histogenetic link between mesothelial and epithelial cells
B. Davidson (2007)
10.1016/j.currproblcancer.2009.06.005
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: non-colorectal indications.
P. Shen (2009)
10.1016/j.ejca.2010.06.130
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
F. Perrone (2010)
10.1016/j.humpath.2012.05.014
Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
N. Ordóñez (2013)
10.1177/1066896917716773
Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma
M. Takeda (2017)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1016/J.HUMPATH.2005.08.008
Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
N. Ordóñez (2005)
10.1186/1477-7819-8-88
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
J. Foster (2010)
10.1186/1476-4598-13-69
Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease
B. Nuvoli (2013)
Peritoneal malignant mesothelioma: case report.
Luigi Tenaglia (2007)
10.1097/PAI.0b013e318159b877
Expression of EGFR in Gastric Stromal Tumors: A Clinicopathologic Study
Xiaofei Qiu (2008)
10.3892/or.2012.1725
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Neetu Kalra (2012)
10.1186/s12885-017-3382-6
Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
Sophie Sneddon (2017)
10.1016/j.jamcollsurg.2013.12.013
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.
E. Levine (2014)
10.5858/arpa.2017-0092-OA
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
R. Tandon (2018)
10.1002/JSO.20266
Malignant peritoneal mesothelioma
K. Bani-Hani (2005)
10.1007/978-1-4939-1578-1_12
Exfoliative Cytology and Effusions
S. Meschter (2015)
10.3919/JJSA.72.2425
A CASE OF PERITONEAL MESOTHELIOMA TREATED WITH CDDP AND PEMETREXED
Yoshihiro Ueda (2011)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
10.1007/s00261-009-9512-0
Recurrent malignant peritoneal mesothelioma: radiological manifestations
F. F. Souza (2009)
10.1016/J.LUNGCAN.2005.10.016
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
10.1038/modpathol.2012.200
Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas
N. Ordóñez (2013)
10.1177/0003702820924726
Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy
Fatlinda Sadiku-Zehri (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar